Cargando…
The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis
Immunotherapy targeting programmed death-ligand 1 (PD-L1) or PD-1 in solid tumors has been shown to be clinically beneficial. However, in colorectal cancer (CRC), only a subset of patients benefit from PD-1/PD-L1 treatment. Previously, we showed that high cysteinyl leukotriene receptor 1 (CysLT(1)R)...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265834/ https://www.ncbi.nlm.nih.gov/pubmed/37316937 http://dx.doi.org/10.1186/s12964-023-01157-6 |
_version_ | 1785058616035770368 |
---|---|
author | Satapathy, Shakti Ranjan Ghatak, Souvik Sjölander, Anita |
author_facet | Satapathy, Shakti Ranjan Ghatak, Souvik Sjölander, Anita |
author_sort | Satapathy, Shakti Ranjan |
collection | PubMed |
description | Immunotherapy targeting programmed death-ligand 1 (PD-L1) or PD-1 in solid tumors has been shown to be clinically beneficial. However, in colorectal cancer (CRC), only a subset of patients benefit from PD-1/PD-L1 treatment. Previously, we showed that high cysteinyl leukotriene receptor 1 (CysLT(1)R) levels are associated with poor prognosis in CRC patients. Recently, we have revealed the role of the tumor promoter CysLT(1)R in drug resistance and stemness in colon cancer (CC) cells. Here, we show the role of the CysLT(1)R/Wnt/β-catenin signaling axis in the regulation of PD-L1 using both in vitro and in vivo preclinical model systems. Interestingly, we found that both endogenous and IFNγ-induced PD-L1 expression in CC cells is mediated through upregulation of CysLT(1)R, which enhances Wnt/β-catenin signaling. Therapeutic targeting of CysLT(1)R with its antagonist montelukast (Mo), as well as CRISPR/Cas9-mediated or doxycycline-inducible functional absence of CysLT(1)R, negatively regulated PD-L1 expression in CC cells. Interestingly, an anti-PD-L1 neutralizing antibody exhibited stronger effects together with the CysLT(1)R antagonist in cells (Apc(mut) or CTNNB1(mut)) with either endogenous or IFNγ-induced PD-L1 expression. Additionally, mice treated with Mo showed depletion of PD-L1 mRNA and protein. Moreover, in CC cells with combined treatment of a Wnt inhibitor and an anti-PD-L1 antibody was effective only in β-catenin-dependent (APC(mut)) context. Finally, analysis of public dataset showed positive correlations between the PD-L1 and CysLT(1)R mRNA levels. These results elucidate a previously underappreciated CysLT(1)R/Wnt/β-catenin signaling pathway in the context of PD-L1 inhibition in CC, which might be considered for improving the efficacy of anti-PD-L1 therapy in CC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-023-01157-6. |
format | Online Article Text |
id | pubmed-10265834 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-102658342023-06-15 The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis Satapathy, Shakti Ranjan Ghatak, Souvik Sjölander, Anita Cell Commun Signal Research Immunotherapy targeting programmed death-ligand 1 (PD-L1) or PD-1 in solid tumors has been shown to be clinically beneficial. However, in colorectal cancer (CRC), only a subset of patients benefit from PD-1/PD-L1 treatment. Previously, we showed that high cysteinyl leukotriene receptor 1 (CysLT(1)R) levels are associated with poor prognosis in CRC patients. Recently, we have revealed the role of the tumor promoter CysLT(1)R in drug resistance and stemness in colon cancer (CC) cells. Here, we show the role of the CysLT(1)R/Wnt/β-catenin signaling axis in the regulation of PD-L1 using both in vitro and in vivo preclinical model systems. Interestingly, we found that both endogenous and IFNγ-induced PD-L1 expression in CC cells is mediated through upregulation of CysLT(1)R, which enhances Wnt/β-catenin signaling. Therapeutic targeting of CysLT(1)R with its antagonist montelukast (Mo), as well as CRISPR/Cas9-mediated or doxycycline-inducible functional absence of CysLT(1)R, negatively regulated PD-L1 expression in CC cells. Interestingly, an anti-PD-L1 neutralizing antibody exhibited stronger effects together with the CysLT(1)R antagonist in cells (Apc(mut) or CTNNB1(mut)) with either endogenous or IFNγ-induced PD-L1 expression. Additionally, mice treated with Mo showed depletion of PD-L1 mRNA and protein. Moreover, in CC cells with combined treatment of a Wnt inhibitor and an anti-PD-L1 antibody was effective only in β-catenin-dependent (APC(mut)) context. Finally, analysis of public dataset showed positive correlations between the PD-L1 and CysLT(1)R mRNA levels. These results elucidate a previously underappreciated CysLT(1)R/Wnt/β-catenin signaling pathway in the context of PD-L1 inhibition in CC, which might be considered for improving the efficacy of anti-PD-L1 therapy in CC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-023-01157-6. BioMed Central 2023-06-14 /pmc/articles/PMC10265834/ /pubmed/37316937 http://dx.doi.org/10.1186/s12964-023-01157-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Satapathy, Shakti Ranjan Ghatak, Souvik Sjölander, Anita The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis |
title | The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis |
title_full | The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis |
title_fullStr | The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis |
title_full_unstemmed | The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis |
title_short | The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis |
title_sort | tumor promoter cysteinyl leukotriene receptor 1 regulates pd-l1 expression in colon cancer cells via the wnt/β-catenin signaling axis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265834/ https://www.ncbi.nlm.nih.gov/pubmed/37316937 http://dx.doi.org/10.1186/s12964-023-01157-6 |
work_keys_str_mv | AT satapathyshaktiranjan thetumorpromotercysteinylleukotrienereceptor1regulatespdl1expressionincoloncancercellsviathewntbcateninsignalingaxis AT ghataksouvik thetumorpromotercysteinylleukotrienereceptor1regulatespdl1expressionincoloncancercellsviathewntbcateninsignalingaxis AT sjolanderanita thetumorpromotercysteinylleukotrienereceptor1regulatespdl1expressionincoloncancercellsviathewntbcateninsignalingaxis AT satapathyshaktiranjan tumorpromotercysteinylleukotrienereceptor1regulatespdl1expressionincoloncancercellsviathewntbcateninsignalingaxis AT ghataksouvik tumorpromotercysteinylleukotrienereceptor1regulatespdl1expressionincoloncancercellsviathewntbcateninsignalingaxis AT sjolanderanita tumorpromotercysteinylleukotrienereceptor1regulatespdl1expressionincoloncancercellsviathewntbcateninsignalingaxis |